Suppr超能文献

微小 RNA-182-5p 通过下调 FOXF2、RECK 和 MTSS1 基因促进人前列腺癌的细胞侵袭和增殖。

MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer.

机构信息

Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, United States of America.

出版信息

PLoS One. 2013;8(1):e55502. doi: 10.1371/journal.pone.0055502. Epub 2013 Jan 30.

Abstract

Recently miR-182 has been reported to be over-expressed in prostate cancer (PC) tissues, however detailed functional analysis of miR-182-5p has not been carried out. The purpose of this study was to: 1. analyze the function of miR-182-5p in prostate cancer, 2. assess its usefulness as a tumor marker, 3. identify miR-182-5p target genes in PC, 4. investigate the potential for miR-182-5p inhibitor to be used in PC treatment. Initially we found that miR-182-5p expression was significantly higher in prostate cancer tissues and cell lines compared to normal prostate tissues and cells. Moreover high miR-182-5p expression was associated with shorter overall survival in PC patients. To study the functional significance of miR-182-5p, we knocked down miR-182-5p with miR-182-5p inhibitor. After miR-182-5p knock-down, prostate cancer cell proliferation, migration and invasion were decreased. We identified FOXF2, RECK and MTSS1 as potential target genes of miR-182-5p using several algorithms which was confirmed by 3'UTR luciferase assay and Western analysis. Knock-down of miR-182-5p also significantly decreased in vivo prostate tumor growth. In conclusion this is the first report documenting that over-expression of miR-182-5p is associated with prostate cancer progression and potentially useful as a prognostic biomarker. Also knock down of miR-182-5p in order to increase expression of tumor suppressor genes FOXF2, RECK and MTSS1 may be of therapeutic benefit in prostate cancer treatment.

摘要

最近有研究报道 miR-182 在前列腺癌(PC)组织中过表达,然而 miR-182-5p 的详细功能分析尚未进行。本研究旨在:1. 分析 miR-182-5p 在前列腺癌中的功能,2. 评估其作为肿瘤标志物的有用性,3. 鉴定 PC 中 miR-182-5p 的靶基因,4. 研究 miR-182-5p 抑制剂在 PC 治疗中的应用潜力。最初我们发现,miR-182-5p 在前列腺癌组织和细胞系中的表达明显高于正常前列腺组织和细胞。此外,miR-182-5p 高表达与 PC 患者总生存时间缩短相关。为了研究 miR-182-5p 的功能意义,我们用 miR-182-5p 抑制剂敲低 miR-182-5p。miR-182-5p 敲低后,前列腺癌细胞增殖、迁移和侵袭能力降低。我们使用几种算法鉴定了 FOXF2、RECK 和 MTSS1 作为 miR-182-5p 的潜在靶基因,这通过 3'UTR 荧光素酶检测和 Western 分析得到了证实。miR-182-5p 的敲低也显著降低了体内前列腺肿瘤的生长。总之,这是首次报道 miR-182-5p 的过表达与前列腺癌进展相关,并可能作为一种预后生物标志物有用。此外,敲低 miR-182-5p 以增加肿瘤抑制基因 FOXF2、RECK 和 MTSS1 的表达可能对前列腺癌治疗具有治疗益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e98/3559583/919e64abf9e6/pone.0055502.g001.jpg

相似文献

2
MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis.
World J Gastroenterol. 2014 Dec 14;20(46):17439-47. doi: 10.3748/wjg.v20.i46.17439.
3
miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1.
Tumour Biol. 2016 Sep;37(9):12023-12032. doi: 10.1007/s13277-016-5058-2. Epub 2016 May 11.
4
miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer.
J Cell Mol Med. 2018 Mar;22(3):1855-1863. doi: 10.1111/jcmm.13469. Epub 2018 Jan 24.
6
Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer.
PLoS One. 2012;7(11):e51056. doi: 10.1371/journal.pone.0051056. Epub 2012 Nov 30.
7
Tumor-Suppressive Function of miR-30d-5p in Prostate Cancer Cell Proliferation and Migration by Targeting NT5E.
Cancer Biother Radiopharm. 2018 Jun;33(5):203-211. doi: 10.1089/cbr.2018.2457.
8
miR-28-5p targets MTSS1 to regulate cell proliferation and apoptosis in esophageal cancer.
Acta Biochim Biophys Sin (Shanghai). 2020 Aug 5;52(8):842-852. doi: 10.1093/abbs/gmaa059.
9
LncRNA MEG3 inhibits the progression of prostate cancer by modulating miR-9-5p/QKI-5 axis.
J Cell Mol Med. 2019 Jan;23(1):29-38. doi: 10.1111/jcmm.13658. Epub 2018 Nov 22.

引用本文的文献

1
Role of the Forkhead box family protein FOXF2 in the progression of solid tumor: systematic review.
J Cancer Res Clin Oncol. 2024 Dec 26;151(1):14. doi: 10.1007/s00432-024-06047-z.
2
Diagnostic Value and Molecular Function of MicroRNAs in Endometrial Diseases: A Systematic Review.
Cancers (Basel). 2024 Jun 30;16(13):2416. doi: 10.3390/cancers16132416.
3
MiR-21 Regulates Growth and Migration of Cervical Cancer Cells by RECK Signaling Pathway.
Int J Mol Sci. 2024 Apr 6;25(7):4086. doi: 10.3390/ijms25074086.
4
MiRNA-related metastasis in oral cancer: moving and shaking.
Cancer Cell Int. 2023 Aug 27;23(1):182. doi: 10.1186/s12935-023-03022-5.
6
The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.
Cancer Cell Int. 2023 Jul 12;23(1):134. doi: 10.1186/s12935-023-02972-0.
9
miRNA in Molecular Diagnostics.
Bioengineering (Basel). 2022 Sep 9;9(9):459. doi: 10.3390/bioengineering9090459.

本文引用的文献

1
Metastasis tumour suppressor-1 and the aggressiveness of prostate cancer cells.
Exp Ther Med. 2011 Jan;2(1):157-162. doi: 10.3892/etm.2010.184. Epub 2010 Dec 2.
4
MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.
J Pathol. 2012 Oct;228(2):204-15. doi: 10.1002/path.4000. Epub 2012 Apr 18.
6
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
7
Involvement of the SKP2-p27(KIP1) pathway in suppression of cancer cell proliferation by RECK.
Oncogene. 2012 Sep 13;31(37):4128-38. doi: 10.1038/onc.2011.570. Epub 2011 Dec 12.
8
miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells.
J Biol Chem. 2011 Dec 30;286(52):44503-11. doi: 10.1074/jbc.M111.262915. Epub 2011 Nov 1.
9
RECK overexpression decreases invasive potential in prostate cancer cells.
Prostate. 2012 Jun 15;72(9):948-54. doi: 10.1002/pros.21498. Epub 2011 Oct 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验